Küçük Can, Esmeray Sönmez Esra, Hatipoğlu Tevfik, Yuan Hongling, Hu Xiaozhou, Ceylan Arda, Siviş Zuhal Önder, Demirağ Bengü, Ataseven Eda, İnce Dilek, Altun Zekiye, Aktaş Safiye, Özsan Nazan, Erdağ Taner Kemal, Ayhan Yavuz Selim, Demir Gündoğan Begümhan, Çetingül Nazan, Özer Erdener, Kutluk Tezer, Olgun Nur
Department of Medical Biology, Faculty of Medicine, Dokuz Eylül University, İzmir, Türkiye.
İzmir Biomedicine and Genome Center, İzmir, Türkiye.
Pediatr Res. 2024 Sep 11. doi: 10.1038/s41390-024-03478-9.
Pediatric Burkitt lymphoma (pBL) is the most common non-Hodgkin lymphoma in children. These patients require prompt diagnosis and initiation of therapy due to rapid tumor growth. The roles of tumor tissue and circulating microRNAs (miRNAs) in the diagnosis or prognostication have not been fully elucidated in pBLs.
Differentially expressed (DE) miRNAs were identified with microRNA sequencing (miRNA-Seq) in tumor tissues and plasma of diagnostic pBLs. The diagnostic potential of total miRNA concentrations and overexpressed miRNAs were evaluated through receiver operating characteristic (ROC) analyses. Log-rank test was employed to evaluate survival differences associated with DE miRNAs. Selected miRNA expressions were cross-validated with quantitative reverse transcription PCR (qRT-PCR).
Total circulating cell-free miRNAs were higher in pBL cases compared to controls. Cancer-associated pathways were enriched among miRNAs differentially expressed in pBL tumor tissues. Several upregulated miRNAs in pBL tumors demonstrated high diagnostic potential. Similarly, ROC analysis of overexpressed plasma miRNAs revealed circulating cell-free or exosomal miRNAs that can distinguish pBLs from control cases. Indeed, integrative analysis of overexpressed circulating exosomal miRNAs showed an enhanced diagnostic potential for certain triple combinations. Kaplan-Meier analyses of DE miRNAs in tumor tissues identified miRNAs predicting overall survival.
Differentially expressed miRNAs in tumor tissue and plasma of pBL have the potential to improve diagnosis and prognosis.
Differentially expressed miRNAs in treatment-naive pediatric Burkitt lymphoma cases have diagnostic or prognostic biomarker potential. This is the first study that applied miRNA-Seq on treatment-naive pediatric Burkitt lymphoma cases for identification of differentially expressed miRNAs both in tumor tissue and plasma samples with diagnostic potential. Through systematic analysis of differentially expressed miRNAs, tumor tissue miRNAs associated with the overall survival of pBLs have been discovered. The clinically significant, differentially expressed miRNAs identified in pediatric Burkitt lymphoma cases can potentially improve the current tissue-based or non-invasive clinical practice in terms of diagnosis or prognostication.
儿童伯基特淋巴瘤(pBL)是儿童中最常见的非霍奇金淋巴瘤。由于肿瘤生长迅速,这些患者需要及时诊断并开始治疗。肿瘤组织和循环微RNA(miRNA)在pBL的诊断或预后中的作用尚未完全阐明。
通过微RNA测序(miRNA-Seq)在诊断为pBL的肿瘤组织和血浆中鉴定差异表达(DE)的miRNA。通过受试者工作特征(ROC)分析评估总miRNA浓度和过表达miRNA的诊断潜力。采用对数秩检验评估与DE miRNA相关的生存差异。选定的miRNA表达通过定量逆转录PCR(qRT-PCR)进行交叉验证。
与对照组相比,pBL病例中循环无细胞miRNA总量更高。癌症相关通路在pBL肿瘤组织中差异表达的miRNA中富集。pBL肿瘤中一些上调的miRNA具有较高的诊断潜力。同样,对过表达的血浆miRNA进行ROC分析,发现循环无细胞或外泌体miRNA可区分pBL和对照病例。事实上,对过表达的循环外泌体miRNA进行综合分析显示,某些三联组合具有增强的诊断潜力。对肿瘤组织中DE miRNA进行Kaplan-Meier分析,确定了预测总生存期的miRNA。
pBL肿瘤组织和血浆中差异表达的miRNA有改善诊断和预后的潜力。
未经治疗的儿童伯基特淋巴瘤病例中差异表达的miRNA具有诊断或预后生物标志物潜力。这是第一项对未经治疗的儿童伯基特淋巴瘤病例应用miRNA-Seq来鉴定肿瘤组织和血浆样本中具有诊断潜力的差异表达miRNA的研究。通过对差异表达miRNA的系统分析,发现了与pBL总生存期相关的肿瘤组织miRNA。在儿童伯基特淋巴瘤病例中鉴定出的具有临床意义的差异表达miRNA,在诊断或预后方面可能会改善当前基于组织或非侵入性的临床实践。